In SUMMIT, tirzepatide reduced the composite of cardiovascular death or worsening heart-failure events by 38% (HR 0.62, 95% CI 0.410.95) and worsening HF events alone by 46% (HR 0.54, 95% CI 0.340.85), with a +6.9-point between-group improvement in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS), an 18-meter improvement in 6-minute walk distance (6MWD), and a placebo-adjusted weight loss of 11.6% [5]
Microscopically-controlled SSE, in comparison with wide excision, achieves lower recurrence rates
Moringa is not known to be a major CYP3A4, CYP2C9, or CYP2D6 inhibitor, and semaglutide has minimal hepatic metabolism
If it is exposed to too much heat or cold, its chemical structure can break down, making it less potent
When should I stop a GLP-1 medication due to side effects